SCHEMBL3354056

SCHEMBL3354056

COC(=O)c1ccc(CS(C)(=O)=O)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.54
KDM4E B2RXH2 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAPT P10636 4/20 0.44
HPGD P15428 1/20 0.43
ALDH1A1 P00352 1/20 0.42
RAB9A P51151 3/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA12 O43570 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA7 P43166 1/20 0.41
STS P08842 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3350381 0.82 GABRP (0.50) MAPTHPGDALDH1A1HSD17B10
SCHEMBL206067 0.82 MAPK1 (0.51) MAPK1KDM4EL3MBTL1MAPTHPGD
SCHEMBL4276177 0.81 NNMT (0.53) KDM4EL3MBTL1SMN1; SMN2
SCHEMBL29695095 0.80 MAPK1 (0.61) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL1441132 0.80 MAPK1 (0.61) MAPK1KDM4EL3MBTL1MAPTHPGD
SCHEMBL204895 0.80 MAPK1 (0.61) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL480126 0.79 MAPK1 (0.59) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL17298235 0.79 MAPK1 (0.59) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL1439028 0.79 MAPK1 (0.59) MAPK1KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL880698 0.79 MAPK1 (0.59) MAPK1KDM4EL3MBTL1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108341819-B Phosphodiesterase inhibitors and uses thereof 南京药捷安康生物科技有限公司 2021-06-15 CN disclosed
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US disclosed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 MAPK1 2548/4885KDM4E 4309/4885L3MBTL1 2946/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP MAPK1 3409/4885KDM4E 4082/4885L3MBTL1 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.